

15 June, 2010

Press Release

Astellas' Brazilian Affiliate Initiates Business Operations

Japan, June 15, 2010 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, "Astellas") today announced that its Brazilian affiliate, Astellas Farma Brasil Importacao e Distribuicao de Medicamentos Ltda. (headquarters: Sao Paulo, Brazil, vice president and general manager: Devaney Baccarin, "Astellas Farma Brasil"), has initiated the marketing of Protopic[®] (tacrolimus), a treatment for atopic dermatitis, and Omnic[®] (tamsulosin), a treatment for functional symptoms of benign prostatic hyperplasia, through Astellas Farma Brasil's own distribution channel.

As a global organization, Astellas has had physical operations in Europe, North America and Asia. In July 2009, Astellas Farma Brasil was established in recognition of the remarkable growth experienced in Brazil's economy and health care sector. In April 2010, Astellas Farma Brasil initiated the marketing of certain proprietary products (Protopic and Omnic) that had previously been marketed by other pharmaceutical companies in Brazil.

In addition to the above two products, Astellas plans to launch other proprietary products in Brazil through Astellas Farma Brasil – such as Mycamine[®] (mycalfungin sodium), an injectable antifungal agent that was approved by Brazilian regulatory authorities in April 2010, and Vesicare[®] (solifenacin succinate), a treatment for overactive bladder, and Omnic OCAS[®] (tamsulosin), modified release formulation of Omnic, both of which are awaiting marketing approval from the regulatory authorities. Through expanding marketing capabilities and launching new products, Astellas Farma Brasil is expected to grow the business in Brazil.

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en/